| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Vifor Pharma AG (SW: VIFN)
VIFN Technical Analysis
4
| As on 22nd Dec 2022 VIFN SHARE Price closed @ 166.15 and we RECOMMEND Buy for LONG-TERM with Stoploss of 146.05 & Strong Buy for SHORT-TERM with Stoploss of 127.02 we also expect STOCK to react on Following IMPORTANT LEVELS. |
VIFNSHARE Price
| Open | 165.00 | Change | Price | % |
| High | 166.50 | 1 Day | 0.80 | 0.48 |
| Low | 165.00 | 1 Week | 3.80 | 2.34 |
| Close | 166.15 | 1 Month | -13.65 | -7.59 |
| Volume | 21850 | 1 Year | 43.85 | 35.85 |
| 52 Week High 192.80 | 52 Week Low 103.20 | ||||
SW Switzerland Most Active Stocks
| CSGN | 0.81 | 0.00% |
| CSGN | 0.81 | 0.00% |
| MBTN | 0.58 | 1.75% |
| ABBN | 34.50 | 0.76% |
| ABBN | 34.50 | 0.76% |
| UBSG | 18.20 | -0.27% |
| UBSG | 18.20 | -0.27% |
| NOVN | 90.17 | -0.22% |
| NOVN | 90.17 | -0.22% |
| NESN | 107.16 | 0.15% |
SW Switzerland Top Gainers Stocks
SW Switzerland Top Losers Stocks
| VIFN Daily Charts |
VIFN Intraday Charts |
Whats New @ Bazaartrend |
VIFN Free Analysis |
|
|
VIFN Important Levels Intraday
| RESISTANCE | 169.04 |
| RESISTANCE | 168.11 |
| RESISTANCE | 167.54 |
| RESISTANCE | 166.97 |
| SUPPORT | 165.33 |
| SUPPORT | 164.76 |
| SUPPORT | 164.19 |
| SUPPORT | 163.26 |
VIFN Forecast April 2024
| 4th UP Forecast | 190.43 |
| 3rd UP Forecast | 182.64 |
| 2nd UP Forecast | 177.83 |
| 1st UP Forecast | 173.02 |
| 1st DOWN Forecast | 159.28 |
| 2nd DOWN Forecast | 154.47 |
| 3rd DOWN Forecast | 149.66 |
| 4th DOWN Forecast | 141.87 |
VIFN Weekly Forecast
| 4th UP Forecast | 178.39 |
| 3rd UP Forecast | 174.46 |
| 2nd UP Forecast | 172.04 |
| 1st UP Forecast | 169.61 |
| 1st DOWN Forecast | 162.69 |
| 2nd DOWN Forecast | 160.26 |
| 3rd DOWN Forecast | 157.84 |
| 4th DOWN Forecast | 153.91 |
VIFN Forecast2024
| 4th UP Forecast | 349.02 |
| 3rd UP Forecast | 290.37 |
| 2nd UP Forecast | 254.12 |
| 1st UP Forecast | 217.87 |
| 1st DOWN Forecast | 114.43 |
| 2nd DOWN Forecast | 78.18 |
| 3rd DOWN Forecast | 41.93 |
| 4th DOWN Forecast | -16.72 |
Vifor Pharma AG ( SW Switzerland Symbol : VIFN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
VIFN Business Profile
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. Address: Rechenstrasse 37, Sankt Gallen, Switzerland, 9014
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service